News Science

IIBAT | REGULATORY SCIENCE SERIES

September 26, 2026

The Role of Contract Research Organisations in the
Regulatory Framework

How CROs navigate pharmaceutical and agricultural regulatory pathways and where they diverge

KEY INSIGHT

The global CRO market is projected to surpass $96 billion by 2028 a clear signal that pharmaceutical and biotech sponsors are increasingly relying on outsourced expertise to meet ever-tightening regulatory demands. Agricultural CROs are similarly expanding as agrochemical companies face heightened scrutiny on environmental safety and residue limits.

IIBAT Editorial | Clinical Research | 8 min read

Introduction

The pharmaceutical and biotechnology industries operate within one of the most demanding regulatory environments in the world. Bringing a new drug, biologic, or medical device to market requires navigating a labyrinth of scientific, ethical, and legal requirements enforced by bodies such as the Central Drugs Standard Control Organisation (CDSCO) in India, the U.S. Food and Drug administration (FDA), and the European Medicines Agency (EMA). In this context, Contract Research Organisations (CROs) have emerged as pivotal intermediaries technical partners that help sponsors translate scientific innovation into regulatory compliant, market ready therapies.

Equally important yet often overlooked is the role CROs play in the agricultural sector. Agrochemical companies rely on CROs to generate the field efficacy, residue, and ecotoxicology data demanded by regulators before a new pesticide, herbicide, or biopesticide can be registered. Though both sectors share the CRO model, their regulatory frameworks, study designs & compliance obligations differ substantially.

For institutions like IIBAT, understanding both dimensions is essential for preparing professionals equipped to operate across life sciences.

What Is a Contract Research Organisation?

A Contract Research Organization is a company that provides outsourced research services to the pharmaceutical, biotechnology, medical device, and agrochemical industries. CROs take on portions or sometimes the entirety of a sponsor’s research activities on a contractual basis. Their scope ranges from early phase drug discovery and toxicology studies to large scale multi country Phase III clinical trials, post marketing surveillance, field crop trials, and environmental fate studies.

What unites all CROs, regardless of sector, is their central function: delivering high quality scientific data under conditions that satisfy regulatory scrutiny. The sponsor remains legally and scientifically responsible for all submitted evidence, but the practical burden of producing that evidence rests with the CRO.

Type your paragraph here

CROs in the Pharmaceutical Regulatory Framework

Pharmaceutical CROs operate under a framework shaped primarily by the International Council for Harmonisation (ICH) guidelines and the regulations of the target market’s health authority. In India, the New Drugs and Clinical Trials Rules, 2019, and Schedule Y of the Drugs and Cosmetics Act, 1940, government clinical research conduct.

Core Regulatory Functions — Pharmaceutical

Protocol Development and Regulatory Strategy

Before a single patient is enrolled, CROs contribute to designing clinical protocols that are scientifically sound and regulatorily defensible. This includes advising on endpoints acceptable to target health authorities, structuring adaptive trial designs, and preparing pre-IND or pre-submission meetings with regulators. Sound regulatory strategy at this stage can shorten approval timelines by years.

Good Clinical Practice (GCP) Compliance

The ICH E6(R2) guideline on Good Clinical Practice is the bedrock of clinical trial regulation globally. CROs implement GCP across every aspect of a trial — from investigator selection and informed consent to data collection, adverse event reporting, and archiving. Trained CRO staff serve as the primary stewards of GCP compliance at the site level, conducting monitoring visits and performing source data verification.

Regulatory Submissions and Dossier Management

Preparing a Common Technical Document (CTD) or eCTD submission for a new drug application is a resource-intensive task requiring deep expertise. Many CROs offer full regulatory affairs services, including the preparation of Investigational Medicinal Product Dossiers (IMPDs), clinical study reports, and responses to agency queries.

Pharmacovigilance and Safety Reporting

Regulatory agencies mandate rapid reporting of Serious Adverse Events (SAEs). CROs providing pharmacovigilance services operate 24/7 safety desks, maintain signal detection systems, and prepare Periodic Safety Update Reports (PSURs) or Development Safety Update Reports (DSURs) submitted to health authorities at defined intervals.

Data Management and Biostatistics

Regulatory submissions depend on the quality of their data. CROs must adhere to 21 CFR Part 11 (FDA) or equivalent standards for electronic records, maintain audit trails, and produce analysis datasets in CDISC-compliant formats (SDTM and ADaM). Biostatisticians are responsible for pre specified statistical analysis plans that cannot be altered after database lock.

CDSCO & INDIA

India’s New Drugs and Clinical Trials Rules, 2019, introduced greater clarity to the roles of sponsors, investigators, ethics committees, and CROs. Indian CROs now operate in an environment of more frequent and rigorous GCP inspections, while the country’s large patient populations and ICH alignment make it a preferred destination for global multi regional trials.

Key Regulatory Responsibilities of Pharmaceutical CROs

Maintaining Standard Operating Procedures (SOPs) that meet or exceed applicable GxP standards and making them available for regulatory inspection.
Qualifying and auditing subcontractors, vendors, and central laboratories to whom any work is further delegated.
Ensuring all staff performing regulated activities are adequately trained, with current and accessible training records.
Retaining essential trial documents for minimum retention periods specified by applicable regulations.
Notifying the sponsor immediately of any finding that could affect participant safety or data integrity.
Cooperating fully with regulatory agency inspections and providing unimpeded access to records, facilities, and personnel.

CROs in the Agricultural Regulatory Framework

Agricultural CROs occupy a distinct regulatory space. Their primary function is to generate the scientific data required for the registration of crop protection products pesticides, herbicides, fungicides, biopesticides, and plant growth regulators under frameworks that emphasize environmental protection, food safety, and ecological risk management rather than human clinical outcomes.

In India, agricultural CROs operate under the Insecticides Act, 1968, and the Insecticides Rules, 1971, with product registration managed by the Central Insecticides Board and Registration Committee (CIBRC). Internationally, OECD Test Guidelines, FAO/WHO Joint Meeting on Pesticide Residues (JMPR) standards, and EPA guidelines (in the US) govern study design and data quality requirements.

Core Regulatory Functions — Agricultural

Field Efficacy Trials

Agricultural CROs design and conduct multi location field trials to demonstrate that a crop protection product delivers reliable efficacy under the target use conditions. Trials must be conducted across representative geographies and agroclimatic zones, following Good Experimental Practice (GEP) the agricultural equivalent of GCP.

Residue Studies and Maximum Residue Level (MRL) Compliance

One of the most critical functions of an agricultural CRO is the generation of residue data. Supervised residue trials establish how much of an active ingredient or its metabolites remain on a food commodity at harvest, enabling regulators to set or confirm Maximum Residue Levels (MRLs) that protect consumer health. Residue data must comply with CODEX Alimentarius standards for international trade acceptance.

Ecotoxicology and Environmental Fate Studies

Before a pesticide is registered, it must be evaluated for its impact on non-target organisms soil microbes, earthworms, pollinators, aquatic organisms, and birds. Agricultural CROs conduct laboratory and semi field ecotoxicology studies following OECD Test Guidelines, and environmental fate studies that track how the compound moves through soil, water, and air.

Physical and Chemical Characterization

CROs support the physico-chemical characterization of agrochemical formulations, including stability studies, storage conditions, and compatibility testing. This data underpins both the product label and the regulatory dossier submitted for registration.

Regulatory Dossier Compilation

Agricultural CROs assemble registration dossiers the agricultural equivalent of the pharmaceutical CTD drawing together efficacy, residue, toxicology, and environmental data into a format acceptable to CIBRC, EPA, or EFSA. Dossier quality directly determines registration timelines.

GOOD EXPERIMENTAL PRACTICE (GEP)

Just as pharmaceutical trials must comply with GCP, agricultural field trials must comply with GEP a set of quality principles ensuring that trial data is accurate, reproducible, and scientifically valid. CIBRC and international authorities increasingly require GEP certification for studies submitted in support of pesticide registration applications.

Pharmaceutical vs. Agricultural CROs: A Regulatory Comparison

While both operate under the CRO model, pharmaceutical and agricultural CROs serve different regulatory masters, generate different types of data, and are subject to different quality frameworks. The table below summarizes the key points of distinction.

Dimension	Pharmaceutical CROs	Agriculture CROs
Regulatory Body	CDSCO (India), FDA (US), EMA (EU)	CIBRC (India), EPA (US), EFSA (EU)
Primary Law	Drugs & Cosmetics Act, 1940; CT Rules 2019	Insecticides Act, 1968; Pesticides Rules, 1971
Key CRO Role	Clinical trial management, GCP compliance, pharmacovigilance	Field efficacy trials, ecotoxicology, residue studies
Guidelines	ICH E6(R2), ICH CTD, Schedule Y	OECD Test Guidelines, FAO/WHO JMPR standards
Data Standards	CDISC (SDTM/ADaM), eCTD	CIPAC methods, GAP (Good Agricultural Practice)
Safety Focus	Human safety – adverse event reporting, PSUR/DSUR	Environmental & food safety – MRL compliance, toxicology
Trial Subjects	Human volunteers / patients	Crops, soil, water, non-target organisms
Ethics Oversight	Institutional Ethics Committee (IEC) mandatory	No equivalent human-subject ethics requirement
Approval Outcome	Marketing Authorisation / Drug Licence	Pesticide Registration / CIB Certificate

Despite these differences, several principles apply across both sectors: the sponsor remains ultimately responsible for data integrity; the CRO must operate within a documented quality system; and regulatory agencies retain the right to inspect CRO facilities and records at any time.

Common Challenges at the Regulatory Interface

Regardless of sector, CROs face persistent challenges in their regulatory roles:

◆ Accountability ambiguity: Sponsors sometimes assume that delegating work to a CRO transfers regulatory risk. It does not. Clear delegation logs and robust quality agreements are regulatory requirements.

◆ Multi-jurisdictional complexity: Global programmes — whether clinical trials or pesticide registrations — must simultaneously satisfy regulatory requirements across multiple countries that, while broadly harmonised, differ in important procedural details.

◆ Evolving standards: Digital technologies, including decentralised trial platforms, AI-driven data analysis, and remote sensing in agriculture, are advancing faster than regulatory guidance. CROs must engage proactively with authorities to shape emerging frameworks.

◆ Staff competency: The quality of a CRO’s regulatory output depends entirely on the training and expertise of its personnel. Continuous professional development is not optional; it is a regulatory imperative.

The Path Forward

As both pharmaceutical pipelines and agrochemical portfolios grow more complex, the regulatory demands on CROs will intensify. The expectation is no longer simply that a CRO will execute a protocol correctly; sophisticated sponsors expect CROs to serve as strategic regulatory partners — anticipating agency concerns before they arise and proposing solutions that maintain both scientific rigour and programme timelines.

In India, the continued strengthening of the CDSCO and CIBRC inspection frameworks means that CROs operating without robust quality systems and trained personnel will find it increasingly difficult to support global-standard programmes. Equally, the harmonisation of Indian regulatory requirements with international standards creates significant opportunity for Indian CROs that invest in building genuine technical expertise.

Building this capacity requires investment in people — professionals who understand not only the rules as written, but the science and ethics that underpin them. This is precisely the gap that IIBAT seeks to address through rigorous, practice-oriented training programmes that equip clinical and agricultural research professionals to meet the demands of a rapidly evolving regulatory environment.

ABOUT IIBAT

The International Institute of Biotechnology and Toxicology (IIBAT) offers specialised training and research programmes in Clinical Research, Regulatory Affairs, Pharmacovigilance, and Agricultural Research — designed to prepare professionals for leadership roles within CROs, pharmaceutical companies, agrochemical organisations, and regulatory agencies.

IIBAT